)
Bubs Australia (BUB) investor relations material
Bubs Australia AGM 2026 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Opening remarks and agenda
Chair opened the meeting at 10:00 with a quorum; the agenda comprised 10 business items, including nine shareholder resolutions, all to be decided by poll.
Shareholders considered the audited FY 2026 financial statements and related reports for the year ended 30 June 2026.
Financial performance review
FY 2026 revenue was AUD 111.9m, up 9.2%; U.S. revenue rose 24% to AUD 65.8m.
Reported EBITDA loss was AUD 1.8m, net loss after tax AUD 4.6m, and gross margin 39.8%; underlying EBITDA was AUD 5.3m, improved from FY 2025.
Inventory rose from AUD 20.1m to AUD 36.3m; at year-end, AUD 10m was drawn on the AUD 20m bank facility and cash was AUD 9.4m.
China revenue was AUD 21.4m, flat YoY; Australia was AUD 18.3m, down 7%; rest-of-world revenue was AUD 6.4m, down 25%.
Board and executive committee updates
Pascal De Petrini and Lori Tauber Marcus joined the Board during 2026; Pascal chairs Audit and Risk, while Lori chairs Nominations and Remuneration.
Chris Rowe became CFO in July 2026 and is expected to relocate to the U.S. in 2027; Jasmin Manner and Annie Chen joined as U.S. President and Global CMO, respectively.
No FY 2026 short-term incentives were awarded to the executive leadership team because the financial performance threshold was not met.
- FDA authorisation and US retail momentum strengthen growth prospects amid $6.0m quarterly cash outflow.BUB
Q1 2027 TU - Permanent FDA approval enables U.S. expansion, innovation, and contract manufacturing opportunities.BUB
FDA announcement - Revenue up 9.2% to AUD 112m ($111.9m), U.S. leads growth, margins to normalize as one-offs subside.BUB
H2 2026 - FY26 revenue expected at $105–115 million, with US expansion and strong liquidity supporting growth.BUB
Trading update - FY26 revenue guidance raised to AUD 120–125m, targeting 22–27% growth and strong EBITDA.BUB
Status update - US-driven 14% revenue growth, 48% US surge, strong margin, but cash and regulatory risks persist.BUB
H1 2026 - Revenue up 29% to $102.5M, first after-tax profit, and strong US-led growth.BUB
H2 2025 - Revenue up 33–34% to AUD 80m, with strong US/China growth and FY25 EBITDA breakeven targeted.BUB
H2 2024 - First-ever half-year net profit and 23% revenue growth, led by US and China, with risks ahead.BUB
H1 2025
)
)
)
)
)
)
)
)